Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Hympavzi (marstacimabum) for the prevention of bleeding in children and adults with hemophilia A and B
- Bupropion (neuraxpharm, bupropioni hydrochloridum) for the treatment of major depressive episodes
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
